Sunitinib in malignant melanoma: a treatment option only for KIT-mutated patients?

Daniele Santini, Bruno Vincenzi, Olga Venditti, Emanuela Dell'Aquila, Anna Maria Frezza, Marianna Silletta, Francesco Maria Guida, Rosario Francesco Grasso, Nicola Silvestris, Gaetano Lanzetta, Giuseppe Tonini

Research output: Contribution to journalArticlepeer-review


Sunitinib has previously been reported to be potentially effective in the treatment of malignant melanomas expressing c-KIT. Here we report on the case of a 77-year-old gentleman affected by a metastatic clear cell carcinoma of the kidney and a metastatic malignant melanoma with liver and lung metastases. Despite the negativity for CD117 and the absence of KIT amplification or mutations in the melanoma specimen, he achieved a partial response both in the lungs and in the liver while on sunitinib (50 mg once/day, 4 weeks on/2 weeks off) for the treatment of kidney cancer. To our knowledge, this represents the first evidence of sunitinib activity in KIT wild-type melanoma. Further studies should be performed to confirm these preliminary data.

Original languageEnglish
Pages (from-to)1809-1811
Number of pages3
JournalFuture Oncology
Issue number12
Publication statusPublished - Dec 2013

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Sunitinib in malignant melanoma: a treatment option only for KIT-mutated patients?'. Together they form a unique fingerprint.

Cite this